Warburg Pincus to Acquire Controlling Stake in PANTHERx Rare

The deal positions the Pittsburgh-based pharmacy to scale its operations and enhance clinical capabilities for patients navigating complex rare disease therapies. CEO Bansi Nagji noted that the partnership with Warburg Pincus provides the resources necessary to continue the company’s independent, patient-first approach. PANTHERx, which holds dual accreditations from the ACHC and URAC, has consistently focused on removing barriers to care through high-touch support and deep therapeutic expertise.

T.J. Carella, managing director at Warburg Pincus, highlighted the firm's interest in the pharmacy’s specialized model and its ability to integrate clinical rigor with manufacturer partnerships. While Nautic Partners will retain a significant interest, the transaction is expected to close in the coming months, pending regulatory approvals. The acquisition follows a period of growth for PANTHERx, which recently secured its ninth MMIT Patient Choice Award in 2026. Financial terms remain undisclosed, though J.P. Morgan Securities served as the lead financial advisor for the incoming investor group.